PIRT
Phosphoinositide-interacting protein
Also known as: PIRT_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P0C851
- Gene
- PIRT
- Ensembl
- ENSG00000233670
- Chromosome
- 17
- Canonical length
- 137 aa
- Protein class
- Predicted membrane proteins, Transporters
- Subcellular location
- Plasma membrane,Cytosol
OverviewNCBI Gene
Predicted to enable phosphatidylinositol bisphosphate binding activity and transmembrane transporter binding activity. Predicted to be involved in regulation of sensory perception of pain. Predicted to act upstream of or within behavioral response to pain; positive regulation of cation channel activity; and response to heat. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2025]
Canonical amino-acid sequenceUniProt
137 residues, UniProt reviewed canonical sequence.
>P0C851|PIRT
1 MTMETLPKVL EVDEKSPEAK DLLPSQTASS LCISSRSESV WTTTPRSNWE IYRKPIVIMS
61 VGGAILLFGV VITCLAYTLK LSDKSLSILK MVGPGFLSLG LMMLVCGLVW VPIIKKKQKH
121 RQKSNFLRSL KSFFLTRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PIRT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 2
- Mean surface accessibility (rSASA)
- 0.54
- Highest tissue expression
- 12 nTPM
Expression across tissuesHPA
Tissue
- midbrain: 12 nTPM
- hypothalamus: 11 nTPM
- spinal cord: 6.7 nTPM
- hippocampal formation: 4.6 nTPM
- colon: 4.1 nTPM
- amygdala: 3.9 nTPM
Single-cell type
- bergmann glia: 22 nCPM
- astrocytes: 21 nCPM
- ependymal cells: 16 nCPM
- oligodendrocyte progenitor cells: 2.6 nCPM
- other brain neurons: 2.4 nCPM
- brain inhibitory neurons: 0.9 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- thalamus: 52 nTPM
- medulla oblongata: 46 nTPM
- midbrain: 34 nTPM
- pons: 29 nTPM
- hypothalamus: 24 nTPM
- spinal cord: 24 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.09
- gnomAD pLI
- 0.58
- gnomAD missense Z
- -0.05
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- phosphatidylinositol bisphosphate binding
- phosphatidylinositol-3,4,5-trisphosphate binding
- transmembrane transporter binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Phosphoinositide-interacting protein
- Phosphoinositide-interacting protein family
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PIRT in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PIRT as an antibody target. Whether an autoantibody or antibody against PIRT could matter depends on whether native PIRT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PIRT is annotated at the cell surface, where native PIRT is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label PIRT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...